Phase 1 β Early testing in a small group of people (usually 20β80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Japan
Aichi Cancer Center ( Site 2702), Nagoya, Aichi-ken National Cancer Center Hospital ( Site 2700), ChΕ«Ε, Tokyo South Korea
Asan Medical Center ( Site 2901), Seoul Samsung Medical Center ( Site 2900), Seoul Taiwan
National Cheng Kung University Hospital ( Site 3001), Tainan